[go: up one dir, main page]

DE602005015174D1 - Verfahren zur herstellung von montelukast-natrium - Google Patents

Verfahren zur herstellung von montelukast-natrium

Info

Publication number
DE602005015174D1
DE602005015174D1 DE602005015174T DE602005015174T DE602005015174D1 DE 602005015174 D1 DE602005015174 D1 DE 602005015174D1 DE 602005015174 T DE602005015174 T DE 602005015174T DE 602005015174 T DE602005015174 T DE 602005015174T DE 602005015174 D1 DE602005015174 D1 DE 602005015174D1
Authority
DE
Germany
Prior art keywords
montelucasts
sodium
producing
present
provides processes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602005015174T
Other languages
English (en)
Inventor
Evgeny Shapiro
Ronit Yahalomi
Valerie Niddam-Hildesheim
Greta Sterimbaum
Kobi Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of DE602005015174D1 publication Critical patent/DE602005015174D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
DE602005015174T 2004-04-21 2005-04-21 Verfahren zur herstellung von montelukast-natrium Expired - Lifetime DE602005015174D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56450404P 2004-04-21 2004-04-21
US58223704P 2004-06-22 2004-06-22
PCT/US2005/014011 WO2005105751A1 (en) 2004-04-21 2005-04-21 Processes for preparing montelukast sodium

Publications (1)

Publication Number Publication Date
DE602005015174D1 true DE602005015174D1 (de) 2009-08-13

Family

ID=34966501

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005015174T Expired - Lifetime DE602005015174D1 (de) 2004-04-21 2005-04-21 Verfahren zur herstellung von montelukast-natrium

Country Status (11)

Country Link
US (1) US7547787B2 (de)
EP (1) EP1646612B1 (de)
JP (1) JP2007532686A (de)
KR (1) KR100815670B1 (de)
AT (1) ATE435209T1 (de)
CA (1) CA2563776A1 (de)
DE (1) DE602005015174D1 (de)
ES (1) ES2327762T3 (de)
IL (1) IL176142A (de)
MX (1) MXPA06012220A (de)
WO (1) WO2005105751A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100486807C (zh) * 2003-09-09 2009-05-13 三菱树脂株式会社 脱模薄片和粘合体
WO2005074935A1 (en) * 2004-01-30 2005-08-18 Teva Pharmaceutical Industries Ltd. Montelukast free acid polymorphs
EP1709002A2 (de) * 2004-01-30 2006-10-11 Teva Pharmaceutical Industries Ltd. Montelukast-natrium-polymorphe
CN101213177A (zh) * 2005-07-05 2008-07-02 特瓦制药工业有限公司 孟鲁司特的纯化
KR20080033425A (ko) * 2005-07-20 2008-04-16 닥터 레디스 래보러토리즈, 인코포레이티드 몬테루캐스트의 제조 공정
IL181607A0 (en) 2006-02-27 2007-07-04 Chemagis Ltd Novel process for preparing montelukast and salts thereof
WO2008001213A1 (en) * 2006-06-26 2008-01-03 Aurobindo Pharma Limited An improved process for the preparation of leukotriene receptor antagonist (montelukast sodium)
EP1886998A1 (de) 2006-08-09 2008-02-13 Esteve Quimica, S.A. Verfahren zur Reinigung von Montelukast und dessen Aminesalzen
US7700776B2 (en) 2006-10-24 2010-04-20 Formosa Laboratories, Inc. Compounds and preparation for montelukast sodium
KR100774088B1 (ko) * 2006-12-14 2007-11-06 한미약품 주식회사 몬테루카스트의 제조방법 및 이에 사용되는 중간체
CZ302238B6 (cs) * 2007-01-09 2011-01-05 Zentiva, A. S. Zpusob prípravy montelukastu
US20080188664A1 (en) * 2007-01-15 2008-08-07 Chemagis Ltd. Process for preparing montelukast sodium containing controlled levels of impurities
CZ302518B6 (cs) * 2007-07-09 2011-06-29 Zentiva, A. S. Zpusob izolace a cištení montelukastu
JP2010539948A (ja) 2007-09-28 2010-12-24 コデクシス， インコーポレイテッド ケトレダクターゼポリペプチドおよびその使用
KR101072896B1 (ko) * 2007-10-09 2011-10-17 한미홀딩스 주식회사 이온성 액체 매개체를 이용한 몬테루카스트산의 제조 방법
DE102007061630B4 (de) 2007-12-20 2013-07-04 Formosa Laboratories, Inc. Neue Verbindungen und Herstellung von Montelukast-Natrium
WO2009138993A1 (en) * 2008-05-13 2009-11-19 Macleods Pharmaceuticals Limited A process for preparation of montelukast sodium salt
ES2605473T3 (es) 2008-05-26 2017-03-14 Laurus Labs Private Limited Un procedimiento mejorado para la preparación de Montelukast y sus sales
KR101123292B1 (ko) 2008-09-26 2012-03-19 주식회사 엘지생명과학 몬테루카스트 나트륨염의 제조방법
WO2011004298A1 (en) 2009-07-09 2011-01-13 Alembic Limited Montelukast hexamethylenediamine salt and its use for the preparation of montelukast sodium
EP2552892A1 (de) 2010-03-31 2013-02-06 KRKA, D.D., Novo Mesto Effiziente synthese zur herstellung von montelukast und neue kristalline form von zwischenprodukten darin
HUP1000425A2 (en) 2010-08-11 2012-03-28 Richter Gedeon Nyrt Process for the production of montelukast sodium
US8471030B2 (en) 2010-12-06 2013-06-25 Orochem Technologies Inc. Purification of montelukast using simulated moving bed
CN105541710B (zh) * 2016-02-22 2018-06-19 齐鲁天和惠世制药有限公司 一种孟鲁司特的合成方法
CN105541711B (zh) * 2016-02-22 2018-06-19 齐鲁天和惠世制药有限公司 一种孟鲁司特的制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5428033A (en) * 1990-10-12 1995-06-27 Merck Frosst Canada, Inc. Saturated hydroxyalkylquinoline acids as leukotriene antagonists
ATE165088T1 (de) * 1990-10-12 1998-05-15 Merck Frosst Canada Inc Ungesättigte hydroxyalkylchinolinsäuren als leukotrien-antagonisten
US5565473A (en) * 1990-10-12 1996-10-15 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
US5856322A (en) * 1990-10-12 1999-01-05 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
IE920499A1 (en) * 1991-02-21 1992-08-26 Merck Frosst Canada Inc Quinoline-containing ketoacids as leukotriene antagonists
TW416948B (en) * 1993-12-28 2001-01-01 Merck & Co Inc Process for the preparation of leukotriene antagonists
US5523477A (en) * 1995-01-23 1996-06-04 Merck & Co., Inc. Process for the preparation of 1-(thiomethyl)-cyclopropaneacetic acid
US5750539A (en) * 1995-06-07 1998-05-12 Merck Frosst Canada Heteroaryl diol acids as leukotriene antagonists
US5952347A (en) * 1997-03-13 1999-09-14 Merck & Co., Inc. Quinoline leukotriene antagonists
GB9812413D0 (en) * 1998-06-10 1998-08-05 Glaxo Group Ltd Compound and its use
FI104718B (fi) 1998-06-18 2000-03-31 Orion Yhtymae Oyj [[4-(2-atsido-3-metyyli-5-oksotetrahydrofuran-2-yyli)fenyyli]hydratsono]propaanidinitriili käytettäväksi referenssiaineena levosimendaanierien analyysissä
US6716452B1 (en) * 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
AU2003209043A1 (en) 2002-02-07 2003-09-02 Dr. Reddy's Laboratories Ltd. Novel anhydrous amorphous forms of montelukast sodium salt
US20050107612A1 (en) * 2002-12-30 2005-05-19 Dr. Reddy's Laboratories Limited Process for preparation of montelukast and its salts
CA2522053C (en) 2003-04-15 2010-06-29 Merck & Co., Inc. Polymorphic form of montelukast sodium
WO2004108679A1 (en) 2003-06-06 2004-12-16 Morepen Laboratories Limited An improved method for the preparation of montelukast acid and sodium salt thereof in amorphous form
JP2007508271A (ja) 2003-10-10 2007-04-05 シントン・ベスローテン・フェンノートシャップ 固体状態のモンテルカスト
WO2005073194A2 (en) 2004-01-28 2005-08-11 Pliva- Istrazivanje I Razvoj D.O.O. Solid forms of montelukast acid
WO2005074935A1 (en) * 2004-01-30 2005-08-18 Teva Pharmaceutical Industries Ltd. Montelukast free acid polymorphs
US7544805B2 (en) 2004-02-03 2009-06-09 Chemagis Ltd. Stable amorphous forms of montelukast sodium
US7189853B2 (en) * 2004-04-15 2007-03-13 Dr. Reddy's Laboratories Limited Process for the preparation of [R-(E)-1-[[[1-[3-[2-[7-chloro-2-quinolinyl]ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid (Montelukast) and its pharmaceutically acceptable salts
US20090143590A1 (en) 2004-07-19 2009-06-04 Matrix Laboratories Ltd. Process for the Preparation of Montelukast and its Salts
PL205637B1 (pl) 2004-10-22 2010-05-31 Inst Farmaceutyczny Sposób wytwarzania kwasu (R,E)-(1-{1-{3-[2-(7-chlorochinolin-2-ylo)etenylo]fenylo}-3-[2-(1-hydroksy-1-metyloetylo)fenylo] propylosulfanylometylo}cyklopropylo)octowego i/lub jego farmaceutycznie dopuszczalnych soli
US20080214822A1 (en) 2004-11-30 2008-09-04 Medichem, S.A. Process For the Preparation of a Leukotriene Antagonist
CN101213177A (zh) 2005-07-05 2008-07-02 特瓦制药工业有限公司 孟鲁司特的纯化

Also Published As

Publication number Publication date
MXPA06012220A (es) 2007-07-18
ES2327762T3 (es) 2009-11-03
US20050256156A1 (en) 2005-11-17
CA2563776A1 (en) 2005-11-10
EP1646612B1 (de) 2009-07-01
KR100815670B1 (ko) 2008-03-20
WO2005105751A1 (en) 2005-11-10
US7547787B2 (en) 2009-06-16
ATE435209T1 (de) 2009-07-15
JP2007532686A (ja) 2007-11-15
IL176142A0 (en) 2006-10-05
EP1646612A1 (de) 2006-04-19
KR20070004114A (ko) 2007-01-05
IL176142A (en) 2010-12-30

Similar Documents

Publication Publication Date Title
DE602005015174D1 (de) Verfahren zur herstellung von montelukast-natrium
DE602005016292D1 (de) Verfahren zur herstellung von glatiramer
DE502006001614D1 (de) Verfahren zur herstellung von 1-alkyl-3-phenyluracilen
DE502006000218D1 (de) Verfahren zur Herstellung von SiOC-verknüpften, linearen Polydialkylsiloxan-Polyoxyalkylen-Blockcopolymeren
ATE443038T1 (de) Verfahren zur herstellung von cinacalcet hydrochlorid
EP1934354A4 (de) Verfahren zur herstellung von hybridsaat
DE502004009763D1 (de) Verfahren zur herstellung von 1-buten
DE602006010302D1 (de) Verfahren zur Herstellung von 5-methyl-2-furfural
DE502005010038D1 (de) Verfahren zur herstellung von 3-pentennitril
EP1813678A4 (de) Verfahren zur herstellung von glykogen
DE602006009562D1 (de) Verfahren zur herstellung von ferrisuccinylcasein
EP1914220A4 (de) Verfahren zur herstellung von 2-hydroxyestern
DE502006004187D1 (de) Verfahren zur herstellung von diorganopolysiloxanen
DE60302139D1 (de) Verfahren zur herstellung von aripiprazole
DE502004005626D1 (de) Verfahren zur herstellung von organoacylphosphiten
DE502006004524D1 (de) Verfahren zur herstellung von 3,7-diaza-bicycloä3.3.1ünonan-verbindungen
ATE405374T1 (de) Verfahren zur herstellung von brillengläsern
ATE516290T1 (de) Verfahren zur herstellung von buprenorphin und derivaten von buprenorphin
DE502005001841D1 (de) Verfahren zur herstellung von 1,4-diphenylazetidinon-derivaten
DE502005000428D1 (de) Verfahren zur Herstellung von 1,2-Diaminocyclohexan-Platin(II)-Komplexen
ATE474842T1 (de) Neues verfahren zur herstellung von 5-amino-3h- thiazoloä4,5-düpyrimidin-2-on
DE602005013895D1 (de) Vorrichtung zur Herstellung von Reifenbestandteilen.
DE602005021110D1 (de) Verfahren zur herstellung von n-piperidino-1,5-diphenylpyrazol-3-carboxamid-derivaten
DE602004014264D1 (de) Verfahren zur herstellung von olanzapin
DE502005007702D1 (de) Verfahren zur herstellung von terrylen-3,4:11,12-t

Legal Events

Date Code Title Description
8364 No opposition during term of opposition